ArticleBlood2014
How I treat smoldering multiple myeloma.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Defining the biological boundaries of daratumumab monotherapy: long-term insights from the CENTAURUS trial in high-risk smoldering multiple myeloma.Translational cancer research · 2026Article
- Plasma Cells as the Key Players of IVF Failure? Unlocking the Enigma of Infertility and In Vitro Fertilization Failure in the Light of Uterine Inflammation.International journal of molecular sciences · 2024Review
- New horizons in our understanding of precursor multiple myeloma and early interception.Nature reviews. Cancer · 2024Review
- Patient preferences for intervention in the setting of precursor multiple myeloma.Blood cancer journal · 2024Article
- Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.JMIR research protocols · 2024Article
- Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.Nature reviews. Clinical oncology · 2022Review
- Diagnosis and Treatment of AL and ATTR Amyloidosis.Journal of the advanced practitioner in oncology · 2021Article
- Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.Frontiers in medicine · 2021Review
- Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Review
- MRI and PET/MRI in hematologic malignancies.Journal of magnetic resonance imaging : JMRI · 2020Review
- [A 55-year-old male with anemia and monoclonal gammopathy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Host-related immunodeficiency in the development of multiple myeloma.Leukemia & lymphoma · 2018Article
- The bone-marrow niche in MDS and MGUS: implications for AML and MM.Nature reviews. Clinical oncology · 2018Review
- Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.Blood advances · 2017Article
- The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Article
- Recent advances in multiple myeloma: a Korean perspective.The Korean journal of internal medicine · 2016Review
- 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Leukemia · 2016Article
- Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.Journal of molecular medicine (Berlin, Germany) · 2016Review
- Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data.Frontiers in oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Smoldering myeloma is a heterogeneous clinical entity where a subset of patients has an indolent course of disease that mimics monoclonal gammopathy of undermined significance, whereas others have a more aggressive course that has been described as "early myeloma." It is defined as either serum M-protein ≥ 3 g/L or ≥ 10% monoclonal plasma cells in the bone marrow. There are currently no molecular factors to differentiate risks of progression for these patients. Current recommendations of therapy continue to be patient observation or patient enrollment in clinical trials. However, new definitions of active multiple myeloma recently agreed upon by the International Myeloma Working Group may alter the timing of therapy. On the basis of emerging data of therapy in these patients, it seems reasonable to believe that future recommendations for therapy of patients with smoldering myeloma will become an increasingly important topic. In this article, we review the current knowledge of this disease and risk factors associated with progression. We also examine biological insights and alterations that occur in the tumor clone and the surrounding bone marrow niche. Finally, we review clinical trials that have been performed in these patients and provide recommendations for follow-up of patients with this unique disease entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.